



Alpa Laboratories Ltd.

33/2, A. B. Road, Pigdamber - 453 446 Distt. INDORE - (M.P.) INDIA
Phone No. : +91-731-429 4567, Fax No.: +91-731-429 4444, Email : mail@alpalabs.com
CIN-L85195MP1988PLC004446

Date: -12th November, 2016

To,
Listing Department,
BSE Limited.
Rotunda Building, P J Towers
Dalal Street, Fort,
Mumbai – 400 001

To,
Listing Department,
National Stock Exchange of India Limited.
'Exchange Plaza', C-1, Block G,
Bandra - Kurla Complex,
Bandra (E), Mumbai – 400 051

Subject: Outcome of Board Meeting under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Reference :- Scrip Code: 532878 ; Scrip Code: ALPA ; ISIN: INE385I01010

Dear Sir/ Madam,

This is to inform you that pursuant to provisions of Regulation 30 & 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the meeting of the Board of Directors of the Company was held today that is on **Saturday, 12th November, 2016** at registered office of the Company situated at 33/2, A.B Road, Pigdamber Rao, Indore, Madhya Pradesh has approved the following matter:

1. Approval of Standalone Un-audited Financial Results of the Company for quarter and six month period ended 30th September, 2016 along with Limited Review Report.


The Board meeting commenced at 3.00 P.M and concluded at 9.30 P.M.

Kindly take same for your records and oblige.

Thanking you,

Yours Faithfully

For Alpa Laboratories Limited


Megha Neema
Company Secretary



Encl: a/a

Financial Results for Quarter ended 30th September 2016						
Particulars	Standalone Results					
	Quarter Ended			Six Month Ended		Year Ended
	Sep-16	Jun-16	Sep-15	For Six Month Ending On 30.09.2016	For Six Month Ending On 30.09.2015	Year Ended March 2016
	Unaudited					Audited
(a) Net sales/income from operations	1204.25	1499.79	1232.55	2704.04	2028.15	5063.25
(Net of Excise duty)						
(b) Other operating income	25.42	13.43	20.31	38.85	51.07	286.96
1. Total income from operations (net) (a+b)	1229.67	1513.22	1252.86	2742.89	2,079.21	5,350.20
(c) Cost of materials consumed	713.21	974.86	462.97	1688.07	1034.22	3186.14
(d) Purchases of stock-in-trade	-	-	-	-	-	-
(e) Changes in inventories of fin. goods, stock-in-pro. & stock-in-trade	-100.35	-66.25	-105.45	-166.60	-464.15	-398.32
(f) Employee benefits expense	190.63	185.13	166.02	375.77	343.20	717.45
(g) Depreciation and amortization expense	18.00	17.62	20.43	35.62	38.94	83.09
(h) Other expenses	215.78	236.23	243.03	452.94	453.94	1163.35
2. Total expenses (c+d+e+f+g+h)	1037.27	1347.59	787.00	2385.79	1406.15	4751.71
3. Profit/ Loss(-) from operations before other income and finance cost and Exceptional items (1-2)	192.40	165.63	465.86	357.10	673.07	598.49
4. Other income	98.89	134.80	148.96	233.51	255.63	609.22
5. Profit/ Loss(-) from ordinary activities before finance costs and Exceptional items (3+4)	291.28	300.43	614.82	590.61	928.70	1207.72
6. Finance costs	55.41	52.82	29.63	108.23	46.70	144.62
7. Profit/ Loss(-) from ordinary activities after finance cost but before exceptional items (5-6)	235.87	247.61	585.19	482.37	882.00	1063.10
8. Exceptional items	211.53	-	-	211.53	-	-
9. Net Profit/ Loss(-) from ordinary activities before tax (7+/-8)	24.34	247.61	585.19	270.84	882.00	1063.10
10. Tax expense	-	-	-	-	-	289.14
11. Net Profit/ Loss(-) from ordinary activities after tax (9-10)	24.34	247.61	585.19	270.84	882.00	773.96
12. Loss from extraordinary activities	-	-	-	-	-	-
13. Net Profit & Loss after tax and Extraordinary Items (11+/-12)	24.34	247.61	585.19	270.84	882.00	773.96
14. Share of Profit (Loss) of Associates	-	-	-	-	-	-
15. Minority Interest (For Consolidated Result Only)	NA	NA	NA	NA	NA	NA
16. Net Profit & loss After Minority Interest and Share of Profit/ Loss of associates (13+14+15)	24.34	247.61	585.19	270.84	882.00	773.96
17. Paid-up equity share capital (Face Value ` 10 Each)	2104.06	2104.06	2104.06	2104.06	2104.06	2104.06
18. Reserves excluding Revaluation Reserves as per bal. sheet of prev. year	-	-	-	-	-	7325.91
19 i Basic and Diluted Earnings per share before extraordinary items ` (not annualized)	0.12	1.18	2.78	1.29	4.19	3.68
20ii Basic and Diluted Earnings per share after extraordinary items ` (not annualized)	0.12	1.18	2.78	1.29	4.19	3.68
Annexure IX – Statement of Assets & Liabilities						
Particulars	Sep 2016	Mar 2016	Notes -			
	Unaudited	Audited				
(a) Share Capital	2104.06	2,104.06	1. In current quarter, an additional expense of ` 2.12 cr. (Include in other expense) has been made as a consequence of settlement of arbitration & dispute with Ranbaxy (Sun Pharmaceutical Industries Limited)			
(b) Reserves and Surplus	7596.76	7,325.91				
A1. Sub-total - Shareholders' Funds (a+b)	9700.82	9429.97	2. The above results have been subjected to Limited Review by the Statutory Auditors, reviewed by Board Audit Committee and have been approved by the Board of Directors at its meeting today.			
(c) Long-term borrowings	-	-				
(d) Deferred tax liabilities (net)	-	-	3. The Company is operating in the single segment of Drugs & Chemicals.			
(e) Other long-term liabilities	59.02	60.42				
A2. Sub-total - Non-Current Liabilities (c+d+e)	59.02	60.42	4. The Provision for Tax may not have been made for the partial/ unaudited periods.			
(f) Short-term borrowings	1354.60	2,422.89				
(g) Trade payables	1633.74	1,862.27	5. The Figures of Previous Year/ Periods may have been regrouped/ reclassified wherever necessary.			
(h) Other current liabilities	387.64	476.65				
(i) Short-term provisions	146.17	463.44				
A3. Sub-Total - Current Liabilities (f+g+h+i)	3522.15	5225.25				
TOTAL - EQUITY AND LIABILITIES (A1+A2+A3)	13281.98	14715.64				
(j) Fixed assets	430.71	452.71				
(k) Capital work-in-progress	0.00	0.49				
(l) Non Current Investments	3153.99	3102.29				
(m) Deferred Tax Assets Net	5.21	5.21				
(n) Long Term loan & Advances	69.10	67.60				
B1. Sub-Total - Non-Current Assets (j+k+l+m+n)	3659.01	3628.30				
(o) Inventories	1445.42	1,499.81				
(p) Trade receivables	3273.92	3,426.49				
(q) Cash and cash equivalents	3446.54	3,476.21				
(r) Short-term loans and advances	1297.90	1,534.98				
(s) Other current assets	159.19	1,149.85				
B2. Sub-Total - Current Assets (o+p+q+r+s)	9622.97	11087.34				
TOTAL - ASSETS (B1+B2)	13281.98	14715.64				

Mahendra



**LIMITED REVIEW REPORT****REVIEW REPORT TO ALPA LABORATORIES LIMITED**

We have reviewed the accompanying statement of unaudited financial results of **M/s Alpa Laboratories Limited for the quarter ended 30th September, 2016**. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the standard on review Engagement (SRE) 2400 Engagement to Review Financial Statement issued by the Institute of Chartered Accountant of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than audit. We have not performed an audit and accordingly we do not express an audit opinion.

Based on our review conducted as above nothing has come to our attention that cause us to believe that the accompanying statement of unaudited results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 including the manner in which in which is to be disclosed, or that it contains any material misstatement.

Place: Indore

Date: This 12th Day of November, 2016

For: C.H. Padliya & Co.

Chartered Accountants

FRN No. 003151C



(S.C. Padliya)

M.No. 071666